8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 17, 2026·SEC
Material company update
Mar 17, 2026·SEC
Trevi Therapeutics, Inc.(TRVI)Earnings, Financials & Key Ratios
TRVI•NASDAQ
$14.26
$2.02B mkt cap·Price updated May 6, 2026
AboutTrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.Show more
- Revenue$0
- EBITDA-$49M+4.3%
- Net Income-$43M+10.8%
- EPS (Diluted)-0.29+38.3%
- ROE-30.23%+42.5%
- ROIC-31.94%+51.2%
- Debt/Equity0.00-60.3%
TRVI Key Insights
Trevi Therapeutics, Inc. (TRVI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 84 (top 16%)
✗Weaknesses
- ✗Shares diluted 43.6% in last year
- ✗Expensive at 11.3x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TRVI Price & Volume
Trevi Therapeutics, Inc. (TRVI) stock price & volume — 10-year historical chart
Loading chart...
TRVI Growth Metrics
Trevi Therapeutics, Inc. (TRVI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM3.67%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM28.2%
Return on Capital
10 Years-116.35%
5 Years-53.3%
3 Years-41.95%
Last Year-34.73%
TRVI Recent Earnings
Trevi Therapeutics, Inc. (TRVI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 5, 2026EPS
$0.09
Est $0.07
-28.6%
Revenue
—
Q2 2026
Mar 17, 2026EPS
$0.06
Est $0.10
+40.0%
Revenue
—
Q4 2025
Nov 13, 2025EPS
$0.08
Est $0.10
+20.0%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.09
Est $0.10
+10.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.09vs $0.07-28.6% | — |
| Q2 2026 | Mar 17, 2026 | $0.06vs $0.10+40.0% | — |
| Q4 2025 | Nov 13, 2025 | $0.08vs $0.10+20.0% | — |
| Q3 2025 | Aug 7, 2025 | $0.09vs $0.10+10.0% | — |
Based on last 12 quarters of dataView full earnings history →
TRVI Peer Comparison
Trevi Therapeutics, Inc. (TRVI) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IDYA | 2.52B | 28.74 | -22.45 | 30.24% | -62.17% | -13.96% | 0.03 | |
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% | |||
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 AXSM | 11.46B | 222.63 | -60.50 | 65.55% | -26.59% | -260.01% | 2.73 | |
 CRL | 8.97B | 181.73 | -62.45 | -0.85% | -3.59% | -4.34% | 0.95 |
Compare TRVI vs Peers
Trevi Therapeutics, Inc. (TRVI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TRVI Income Statement
Trevi Therapeutics, Inc. (TRVI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 23K | 39K | 47K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | -23K▲ 0% | -39K▼ 69.6% | -47K▼ 20.5% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | 100% | - | -69.57% | -20.51% | 100% | - | - | - | - | - |
| Operating Expenses | 8.24M | 18.41M | 26.64M | 32.49M | 32.48M | 29.91M | 33.92M | 51.52M | 49.33M | 52.77M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 2.14M | 4.34M | 7.31M | 10.16M | 9.49M | 10.07M | 10.24M | 12.15M | 15.85M | 17.16M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 6.09M | 14.07M | 19.34M | 22.33M | 22.98M | 19.83M | 23.68M | 39.38M | 33.48M | 35.61M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -24K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.24M▲ 0% | -18.41M▼ 123.5% | -26.64M▼ 44.7% | -32.49M▼ 21.9% | -32.48M▲ 0.0% | -29.91M▲ 7.9% | -33.92M▼ 13.4% | -51.52M▼ 51.9% | -49.33M▲ 4.3% | -52.77M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 4.5% | -123.48% | -44.75% | -21.93% | 0.04% | 7.91% | -13.43% | -51.89% | 4.26% | - |
| EBITDA | -8.23M | -18.39M | -26.61M | -32.44M | -32.43M | -29.86M | -33.8M | -51.38M | -49.18M | -52.66M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 4.5% | -123.31% | -44.72% | -21.93% | 0.05% | 7.9% | -13.18% | -52% | 4.27% | -3.38% |
| D&A (Non-Cash Add-back) | 4K | 23K | 39K | 47K | 50K | 43K | 123K | 147K | 144K | 107K |
| EBIT | -8.24M | -20.5M | -26.64M | -32.32M | -32.76M | -28.02M | -28.71M | -47.94M | -42.82M | -32.47M |
| Net Interest Income | -3.27M | -18K | 792K | -278K | -1.19M | 960K | 4.36M | 3.6M | 6.54M | 5.41M |
| Interest Income | 69K | 156K | 792K | 178K | 10K | 1.74M | 4.75M | 3.6M | 6.54M | 5.41M |
| Interest Expense | 3.34M | 174K | 0 | 456K | 1.2M | 780K | 391K | 4K | 0 | 0 |
| Other Income/Expense | -4.65M | -2.26M | 577K | -287K | -1.49M | 719K | 4.83M | 3.58M | 6.5M | 7.09M |
| Pretax Income | -12.89M▲ 0% | -20.67M▼ 60.4% | -26.07M▼ 26.1% | -32.78M▼ 25.7% | -33.96M▼ 3.6% | -29.19M▲ 14.1% | -29.1M▲ 0.3% | -47.94M▼ 64.8% | -42.82M▲ 10.7% | -45.68M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | -26K | -124K | -18K | -18K | -21K | -36K | -32K | -30K | -64K | -72K |
| Effective Tax Rate % | 0.2% | 0.6% | 0.07% | 0.05% | 0.06% | 0.12% | 0.11% | 0.06% | 0.15% | 0.16% |
| Net Income | -12.86M▲ 0% | -20.55M▼ 59.8% | -26.05M▼ 26.8% | -32.76M▼ 25.8% | -33.94M▼ 3.6% | -29.15M▲ 14.1% | -29.07M▲ 0.3% | -47.91M▼ 64.8% | -42.76M▲ 10.8% | -45.61M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -15.99% | -59.76% | -26.79% | -25.75% | -3.61% | 14.11% | 0.3% | -64.84% | 10.75% | 3.67% |
| Net Income (Continuing) | -12.86M | -20.55M | -26.05M | -32.76M | -33.94M | -29.15M | -29.07M | -47.91M | -42.76M | -45.61M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.43▲ 0% | -2.29▼ 60.1% | -1.46▲ 36.2% | -1.81▼ 24.0% | -1.49▲ 17.7% | -0.45▲ 69.8% | -0.29▲ 35.6% | -0.47▼ 62.1% | -0.29▲ 38.3% | -▲ 0% |
| EPS Growth % | -107.25% | -60.14% | 36.24% | -23.97% | 17.68% | 69.8% | 35.56% | -62.07% | 38.3% | 28.2% |
| EPS (Basic) | -1.43 | -2.29 | -1.46 | -1.81 | -1.49 | -0.45 | -0.29 | -0.47 | -0.29 | - |
| Diluted Shares Outstanding | 8.97M | 8.97M | 17.83M | 18.06M | 22.84M | 64.54M | 99.03M | 101.04M | 145.1M | 0 |
| Basic Shares Outstanding | 8.97M | 8.97M | 17.83M | 18.06M | 22.84M | 64.54M | 99.03M | 101.04M | 145.1M | 0 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TRVI Balance Sheet
Trevi Therapeutics, Inc. (TRVI) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 22.16M | 18.79M | 59.55M | 46.27M | 37.96M | 122.62M | 87.55M | 109.43M | 191.66M | 176.12M |
| Cash & Short-Term Investments | 22.02M | 17.16M | 57.31M | 45M | 36.83M | 120.51M | 82.97M | 107.62M | 188.26M | 171.78M |
| Cash Only | 22.02M | 17.16M | 57.31M | 45M | 36.83M | 12.59M | 32.4M | 34.1M | 18.91M | 19.41M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 107.92M | 50.57M | 73.53M | 169.35M | 152.37M |
| Accounts Receivable | 0 | 184K | 558K | 0 | 241K | 0 | 0 | 532K | 986K | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 63K | 1.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | 22.15K | - | - | - | - | - | - | - | - |
| Other Current Assets | 49K | 0 | 77K | 265K | 0 | 1.31M | 955K | 335K | 2.41M | 4.34M |
| Total Non-Current Assets | 66K | 1.7M | 449K | 862K | 518K | 399K | 1.86M | 1.47M | 1.78M | 3.48M |
| Property, Plant & Equipment | 14K | 149K | 430K | 330K | 184K | 194K | 1.56M | 1.23M | 855K | 875K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 52K | 1.55M | 19K | 532K | 334K | 205K | 297K | 243K | 928K | 3.71M |
| Total Assets | 22.23M▲ 0% | 20.49M▼ 7.8% | 60M▲ 192.8% | 47.13M▼ 21.4% | 38.48M▼ 18.4% | 123.02M▲ 219.7% | 89.4M▼ 27.3% | 110.9M▲ 24.0% | 193.44M▲ 74.4% | 179.61M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | 164.34% | -7.82% | 192.84% | -21.45% | -18.37% | 219.73% | -27.32% | 24.05% | 74.43% | 513.85% |
| Total Current Liabilities | 7.13M | 2.68M | 5.2M | 5.55M | 12.72M | 13.4M | 5.82M | 10.51M | 9.75M | 7.12M |
| Accounts Payable | 537K | 603K | 1.6M | 2.02M | 2.85M | 2.86M | 1.81M | 3.41M | 3.91M | 2.21M |
| Days Payables Outstanding | - | 9.57K | 14.96K | 15.66K | - | - | - | - | - | - |
| Short-Term Debt | 5.29M | 0 | 0 | 0 | 5.83M | 7M | 0 | 0 | 307K | 318K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 776K | 0 | 114K | 0 | 1.61M | 2.54M | 5.53M | 4.58M |
| Current Ratio | 3.11x | 7.02x | 11.45x | 8.33x | 2.98x | 9.15x | 15.03x | 10.41x | 19.66x | 19.66x |
| Quick Ratio | 3.10x | 6.50x | 11.45x | 8.33x | 2.98x | 9.15x | 15.03x | 10.41x | 19.66x | 19.66x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 325K | 506K | 257K | 14.29M | 8.68M | 2.16M | 1.03M | 747K | 446K | 364K |
| Long-Term Debt | 0 | 1.1M | 0 | 13.95M | 8.65M | 2.15M | 0 | 0 | 0 | 364K |
| Capital Lease Obligations | 0 | 46K | 257K | 144K | 24K | 2K | 1.03M | 747K | 446K | 1.58M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 325K | 460K | 0 | 196K | 0 | 3K | 0 | 0 | 0 | 0 |
| Total Liabilities | 7.45M | 3.18M | 5.46M | 19.85M | 21.4M | 15.56M | 6.86M | 11.26M | 10.2M | 7.48M |
| Total Debt | 5.29M | 1.1M | 356K | 14.21M | 14.63M | 9.18M | 1.34M | 1.03M | 753K | 682K |
| Net Debt | -16.73M | -16.07M | -56.96M | -30.79M | -22.2M | -3.41M | -31.06M | -33.06M | -18.16M | -18.73M |
| Debt / Equity | 0.36x | 0.06x | 0.01x | 0.52x | 0.86x | 0.09x | 0.02x | 0.01x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.01x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.36x |
| Interest Coverage | -2.46x | -117.79x | - | -70.88x | -27.25x | -35.93x | -73.42x | -11984.25x | - | - |
| Total Equity | 14.78M▲ 0% | 17.31M▲ 17.1% | 54.55M▲ 215.2% | 27.28M▼ 50.0% | 17.07M▼ 37.4% | 107.46M▲ 529.3% | 82.55M▼ 23.2% | 99.64M▲ 20.7% | 183.24M▲ 83.9% | 172.13M▲ 0% |
| Equity Growth % | 184.88% | 17.11% | 215.16% | -49.98% | -37.41% | 529.34% | -23.18% | 20.71% | 83.9% | 578.77% |
| Book Value per Share | 1.65 | 1.93 | 3.06 | 1.51 | 0.75 | 1.66 | 0.83 | 0.99 | 1.26 | 36.49 |
| Total Shareholders' Equity | 14.78M | 17.31M | 54.55M | 27.28M | 17.07M | 107.46M | 82.55M | 99.64M | 183.24M | 172.13M |
| Common Stock | 4K | 101K | 18K | 19K | 29K | 60K | 68K | 94K | 128K | 128K |
| Retained Earnings | -84.43M | -109.5M | -114.22M | -146.98M | -180.92M | -210.07M | -239.13M | -287.05M | -329.8M | -343M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -23K | -46K | 0 | 0 | 0 | -122K | -29K | 61K | 148K | -190K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TRVI Cash Flow Statement
Trevi Therapeutics, Inc. (TRVI) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -7.97M | -18.29M | -23.09M | -29M | -28.95M | -28.18M | -31.71M | -38.26M | -42.09M | -42.09M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 28.74% | -129.35% | -26.25% | -25.58% | 0.19% | 2.66% | -12.55% | -20.64% | -10.02% | -33.92% |
| Net Income | -12.86M | -20.55M | -26.05M | -32.76M | -33.94M | -29.15M | -29.07M | -47.91M | -42.76M | -45.61M |
| Depreciation & Amortization | 4K | 23K | 39K | 47K | 50K | 43K | 123K | 147K | 144K | 141K |
| Stock-Based Compensation | 205K | 496K | 1.13M | 2.42M | 2.54M | 2.33M | 2.25M | 3.59M | 5.18M | 6.17M |
| Deferred Taxes | 1.35M | 0 | 0 | 0 | -82K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.6M | 2.3M | 215K | 236K | 974K | -162K | -1.17M | -907K | -1.17M | -6.61M |
| Working Capital Changes | 722K | -568K | 1.58M | 1.06M | 1.51M | -1.23M | -3.85M | 6.83M | -3.49M | 608K |
| Change in Receivables | -30 | -135K | -374K | 293K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 92K | 66K | 777K | 417K | 831K | 9K | -1.05M | 1.6M | -598K | -88K |
| Cash from Investing | -13K | -158K | -9K | -32K | 0 | -107.37M | 59.43M | -21.53M | -94.11M | -67.19M |
| Capital Expenditures | -13K | -158K | -9K | -32K | 0 | -159K | -137K | -35K | -12K | -114K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | -829K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 829K | 0 | 1.37M | 1.64M | 981K |
| Cash from Financing | 21.72M | 3.63K | 73.21M | 16.72M | 20.77M | 111.31M | -7.91M | 61.48M | 121.01M | 112.53M |
| Debt Issued (Net) | -8.25M | -4.81M | 0 | 14M | -68K | -5.83M | -9.41M | -126K | 0 | 0 |
| Equity Issued (Net) | 29.92M | 8.96M | 75.06M | 3.13M | 21.18M | 105.41M | 1.71M | 61.15M | 120.3M | 109.95M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -1.53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 52K | -520K | -1.85M | -415K | -340K | 11.73M | -211K | 464K | 714K | 2.58M |
| Net Change in Cash | 13.73M▲ 0% | -14.82M▼ 207.9% | 50.11M▲ 438.2% | -12.31M▼ 124.6% | -8.17M▲ 33.6% | -24.24M▼ 196.7% | 19.81M▲ 181.7% | 1.7M▼ 91.4% | -15.18M▼ 993.1% | 38K▲ 0% |
| Free Cash Flow | -7.99M▲ 0% | -18.45M▼ 131.0% | -23.1M▼ 25.2% | -29.03M▼ 25.7% | -28.95M▲ 0.3% | -28.33M▲ 2.1% | -31.85M▼ 12.4% | -38.29M▼ 20.2% | -42.1M▼ 10.0% | -31.94M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 28.63% | -130.96% | -25.22% | -25.67% | 0.3% | 2.11% | -12.4% | -20.23% | -9.95% | 22.67% |
| FCF per Share | -0.89 | -2.06 | -1.30 | -1.61 | -1.27 | -0.44 | -0.32 | -0.38 | -0.29 | -0.29 |
| FCF Conversion (FCF/Net Income) | 0.62x | 0.89x | 0.89x | 0.89x | 0.85x | 0.97x | 1.09x | 0.80x | 0.98x | 0.70x |
| Interest Paid | 0 | 0 | 0 | 180K | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TRVI Key Ratios
Trevi Therapeutics, Inc. (TRVI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -87.02% | -128.07% | -72.51% | -80.07% | -153.03% | -46.82% | -30.59% | -52.59% | -30.23% | -24.53% |
| Return on Invested Capital (ROIC) | - | -1115.19% | - | - | - | -45.35% | -32.72% | -65.46% | -31.94% | -31.94% |
| Debt / Equity | 0.36x | 0.06x | 0.01x | 0.52x | 0.86x | 0.09x | 0.02x | 0.01x | 0.00x | 0.00x |
| Interest Coverage | -2.46x | -117.79x | - | -70.88x | -27.25x | -35.93x | -73.42x | -11984.25x | - | - |
| FCF Conversion | 0.62x | 0.89x | 0.89x | 0.89x | 0.85x | 0.97x | 1.09x | 0.80x | 0.98x | 0.70x |
TRVI SEC Filings & Documents
Trevi Therapeutics, Inc. (TRVI) SEC filings — annual & quarterly reports (10-K, 10-Q)
TRVI Frequently Asked Questions
Trevi Therapeutics, Inc. (TRVI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Trevi Therapeutics, Inc. (TRVI) grew revenue by 0.0% over the past year. Growth has been modest.
Trevi Therapeutics, Inc. (TRVI) reported a net loss of $45.6M for fiscal year 2025.
Dividend & Returns
Trevi Therapeutics, Inc. (TRVI) has a return on equity (ROE) of -30.2%. Negative ROE indicates the company is unprofitable.
Trevi Therapeutics, Inc. (TRVI) had negative free cash flow of $31.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More TRVI
Trevi Therapeutics, Inc. (TRVI) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates